Levosimendan Tillomed

Active Ingredient:: Levosimendan
Origin:: EU

Levosimendan Tillomed (Levosimendan)

Q: What is Levosimendan Tillomed used for?

Levosimendan Tillomed is used in the management of acute decompensated heart failure and related low‑output states. It provides rapid improvement in cardiac contractility and reduces vascular resistance, helping to restore adequate tissue perfusion when standard therapies are insufficient.

Q: How does levosimendan work?

Levosimendan works by binding to troponin C, making the heart muscle more responsive to existing calcium, which strengthens each contraction without increasing calcium influx. At the same time, it opens ATP‑sensitive potassium channels in blood‑vessel walls, producing vasodilation and lowering the workload on the heart.

Q: What is the usual dose of levosimendan?

The dosing regimen for levosimendan is individualized by the prescribing clinician based on the patient’s clinical status, weight, and response. Typically, a loading dose may be followed by a continuous infusion, but exact amounts and duration must be determined by a qualified healthcare professional.

Q: Is levosimendan safe in pregnancy or breastfeeding?

Safety data for levosimendan during pregnancy and lactation are limited. Because potential risks cannot be excluded, the drug should be used only if the expected benefit justifies the potential hazard to the fetus or infant, and it is generally avoided unless absolutely necessary.

Q: How do I order Levosimendan Tillomed from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Q: How does levosimendan compare with other inotropes such as dobutamine?

Unlike traditional inotropes like dobutamine, which increase intracellular calcium, levosimendan enhances contractility by sensitizing troponin C and adds vasodilatory effects through potassium‑channel activation. This dual action can improve cardiac output while potentially causing less myocardial oxygen consumption and offering a broader hemodynamic profile.

Q: How should Levosimendan Tillomed be stored and handled?

Levosimendan Tillomed should be stored refrigerated at 2‑8 °C, protected from light, and never frozen. The vial must be kept in its original packaging until use, and any unused portion should be discarded according to local regulations to maintain product integrity.

Q: How is Levosimendan administered?

Levosimendan is administered intravenously, usually as an initial loading infusion followed by a continuous maintenance infusion. The infusion is given through a calibrated IV set under close hemodynamic monitoring in a hospital setting, ensuring precise control of rate and duration.

Q: What are the most serious risks to watch for with levosimendan?

The most serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare allergic reactions such as anaphylaxis. Patients should be monitored continuously for blood pressure, heart rhythm and signs of ischemia throughout the infusion and for a period afterward.

Q: Who should not receive levosimendan?

Levosimendan is contraindicated in patients with systolic blood pressure below 90 mmHg, severe obstructive cardiomyopathy, uncontrolled ventricular arrhythmias, or known hypersensitivity to the drug or its excipients. Caution is also advised in severe renal or hepatic impairment.

Levosimendan, the active ingredient in Levosimendan Tillomed, is a calcium sensitizer / inodilator presented as an intravenous formulation for intravenous use. It is employed to improve cardiac contractility and reduce symptoms in patients with acute decompensated heart failure, particularly when conventional therapy is insufficient.

GNH India supplies Levosimendan Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to healthcare institutions across global markets.

Manufacturer / TM Owner

Tillomed Pharma Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Levosimendan is indicated for conditions within the heart failure spectrum where enhanced cardiac output is required.

Acute decompensated heart failure: improves cardiac output and relieves pulmonary congestion.
Chronic heart failure (intermittent infusion): provides temporary hemodynamic support and may improve functional status.
Low cardiac output syndrome after cardiac surgery: stabilizes hemodynamics and facilitates weaning from mechanical support.

How It Works

Levosimendan increases cardiac contractility by binding to troponin C and sensitizing it to calcium, thereby enhancing the force of contraction without raising intracellular calcium levels. Simultaneously, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and reducing after‑load. The combined inotropic and vasodilatory actions improve cardiac output while preserving myocardial oxygen consumption.

Side Effects

Levosimendan may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects

Hypotension: drop in blood pressure, especially after loading dose.
Headache: mild to moderate intensity.
Nausea: occasional gastrointestinal upset.
Tachycardia: increased heart rate.
Vomiting: occasional.

Serious or Rare Side Effects

Ventricular arrhythmias: potentially life‑threatening rhythm disturbances.
Myocardial ischemia: chest pain due to reduced coronary perfusion.
Severe hypotension: refractory low blood pressure requiring intervention.
Allergic reactions: rash, pruritus, or anaphylaxis.
Pulmonary edema worsening: paradoxical fluid accumulation.

Precautions & Warnings

When using levosimendan, several safety considerations should be observed.

Blood pressure monitoring: check systolic pressure before and during infusion.
Cardiac rhythm surveillance: observe for arrhythmias, especially in patients with pre‑existing conduction disorders.
Renal function assessment: adjust therapy in severe renal impairment.
Hepatic function assessment: use caution in moderate to severe liver disease.
Contraindication in severe hypotension: avoid if systolic BP < 90 mmHg.
Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Avoid Interactions

Levosimendan can interact with several concomitant medicines; interactions are grouped by clinical significance.

Major Interactions (Avoid)

Concurrent use with other potent vasodilators (e.g., nitroglycerin): may cause profound hypotension.
Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase levosimendan plasma levels.
Other inotropes (e.g., dobutamine) at high doses: risk of excessive cardiac stimulation.

Moderate Interactions (Monitor Closely)

Beta‑blockers: may blunt desired inotropic effect.
Diuretics: synergistic effect on blood pressure, monitor volume status.
Anticoagulants (e.g., warfarin): possible alteration in bleeding risk, monitor INR.

Frequently Asked Questions

Levosimendan Tillomed is used in the management of acute decompensated heart failure and related low‑output states. It provides rapid improvement in cardiac contractility and reduces vascular resistance, helping to restore adequate tissue perfusion when standard therapies are insufficient.

Levosimendan works by binding to troponin C, making the heart muscle more responsive to existing calcium, which strengthens each contraction without increasing calcium influx. At the same time, it opens ATP‑sensitive potassium channels in blood‑vessel walls, producing vasodilation and lowering the workload on the heart.

The dosing regimen for levosimendan is individualized by the prescribing clinician based on the patient’s clinical status, weight, and response. Typically, a loading dose may be followed by a continuous infusion, but exact amounts and duration must be determined by a qualified healthcare professional.

Safety data for levosimendan during pregnancy and lactation are limited. Because potential risks cannot be excluded, the drug should be used only if the expected benefit justifies the potential hazard to the fetus or infant, and it is generally avoided unless absolutely necessary.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Unlike traditional inotropes like dobutamine, which increase intracellular calcium, levosimendan enhances contractility by sensitizing troponin C and adds vasodilatory effects through potassium‑channel activation. This dual action can improve cardiac output while potentially causing less myocardial oxygen consumption and offering a broader hemodynamic profile.

Levosimendan Tillomed should be stored refrigerated at 2‑8 °C, protected from light, and never frozen. The vial must be kept in its original packaging until use, and any unused portion should be discarded according to local regulations to maintain product integrity.

Levosimendan is administered intravenously, usually as an initial loading infusion followed by a continuous maintenance infusion. The infusion is given through a calibrated IV set under close hemodynamic monitoring in a hospital setting, ensuring precise control of rate and duration.

The most serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare allergic reactions such as anaphylaxis. Patients should be monitored continuously for blood pressure, heart rhythm and signs of ischemia throughout the infusion and for a period afterward.

Levosimendan is contraindicated in patients with systolic blood pressure below 90 mmHg, severe obstructive cardiomyopathy, uncontrolled ventricular arrhythmias, or known hypersensitivity to the drug or its excipients. Caution is also advised in severe renal or hepatic impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 28 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.